CNS Drug Innovation to Overcome Neurodegenerative Diseases

　We have developed model mice for Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, cerebral infarction, depression, anxiety, epilepsy, mental retardation, and autism, and have established systems for evaluating brain function and elucidating the mechanisms of disease onset. In addition, based on the results of our research into the pathogenesis of these diseases, we have been working to develop treatments and disease prediction technologies for the various diseases mentioned above. With the vision of “advanced brain drug discovery to overcome neurodegenerative diseases”, we aim to create a society with healthy longevity by creating and commercializing academic research seeds and implementing them in society. Specifically, we aim to achieve a society with healthy longevity without dementia or motor disorders by preventing and curing diseases before they occur by realizing early treatment intervention at each step of disease pathology, early prediction, and fundamental treatment.

Development of a treatment for Lewy body diseases

Development of FABP-targeted drugs that can inhibit the propagation of α-synuclein, the causative protein of Lewy body disease, as well as its intracellular uptake and aggregation.

More information

Development of a treatment for Alzheimer's disease

Development of proteasome-targeted drugs that can promote the degradation of amyloid-β protein, which is the causative protein in Alzheimer's disease, activating CaMKII.

More information

Discriminating technology of neurodegenerative diseases

Development of a method that can predict and differentiate Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease using plasma biomarkers

More information

Elucidation of the Pathogenesis of Lewy Body Disease

Elucidation of the molecular mechanisms of the uptake, propagation, and toxicity of α-synuclein, a causative protein in Parkinson's disease and dementia with Lewy bodies

More information

Elucidation of the Pathogenesis of Hereditary Diseases

Molecular genetic analysis of hereditary dystonia, including dopa-responsive dystonia, hereditary Parkinson's disease, and other hereditary diseases

More information

Lewy body pathology and gut-brain axis

Establishment of a peripheral-to-central propagation model of the causative protein alpha-synuclein in Parkinson's disease and elucidation of the molecular mechanism

More information

This homepage is operated with the aim of gaining the understanding of the general public by widely communicating the results of research and therapeutic development from the Grant-in-Aid for Scientific Research (KAKENHI), the Japan Agency for Medical Research and Development (AMED) Translational Research Strategic Promotion Program, and the Japan Science and Technology Agency (JST) University-Launched New Industry Creation Fund Program Startup Ecosystem Co-Creation Program (MASP).

CNS Drug Innovation

Main Laboratory
Institute of Biomedical Sciences,
Fukushima Medical University
1 Hikarigaoka, Fukushima 960-1295, Japan
https://researchmap.jp/ichiro_kawahata
+81-24-547-1968 (direct) E-Mail